Oral pretreatment with Escherichia coli Nissle 1917 enhances the host's defense against influenza A virus infection

Abstract

Influenza A viruses (IAVs) pose a significant threat to global health, causing annual epidemics and occasional pandemics with substantial morbidity and mortality. Despite the availability of vaccines and antiviral therapies, the development of novel preventive and therapeutic strategies remains a critical research focus. In this study, we evaluated the protective effects of orally administering Escherichia coli Nissle 1917 in IAV-infected mice and elucidated its mechanisms of action by analyzing cecal microbiota and plasm metabolome profiles. Oral administration of E. coli Nissle 1917 alleviated respiratory symptoms, reduced weight loss, and mitigated pathological injury in mice infected with H9N2 or H1N1 IAV. These protective effects were mediated through the modulation of gut microbiota diversity, which increased the abundance of Bacteroides and Akkermansia, correlating with elevated pipecolic acid levels and ultimately aiding in defense against IAV infection in mice. Notably, we identified that the circulating metabolic molecule pipecolic acid plays a significant role in fighting IAV infection. Our findings suggest the potential usefulness of E. coli Nissle 1917 or pipecolic acid in influenza prevention.

Keywords

Escherichia coli Nissle 1917 / gut microbiome / influenza A virus / metabolite / pipecolic acid

References

[1] Johnson NPAS, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002; 76: 105–115.

[2] Jester B, Uyeki TM, Jernigan DB, Tumpey TM. Historical and clinical aspects of the 1918 H1N1 pandemic in the United States. Virology. 2019; 527: 32–37.

[3] Widdowson MA, Bresee JS, Jernigan DB. The global threat of animal influenza viruses of zoonotic concern: then and now. J Infect Dis. 2017; 216: S493–S498.

[4] Nagy A, Lee J, Mena I, Henningson J, Li Y, Ma J, et al. Recombinant Newcastle disease virus expressing H9 HA protects chickens against heterologous avian influenza H9N2 virus challenge. Vaccine. 2016; 34: 2537–2545.

[5] Kim H, Webster RG, Webby RJ. Influenza virus: dealing with a drifting and shifting pathogen. Viral Immunol. 2018; 31: 174–183.

[6] Bi Y, Li J, Shi W. The time is now: a call to contain H9N2 avian influenza viruses. Lancet Microbe. 2022; 3: e804–e805.

[7] Świerczyńska M, Mirowska-Guzel DM, Pindelska E. Antiviral drugs in influenza. Int J Environ Res Public Health. 2022; 19: 3018.

[8] The Lancet. H5N1: international failures and uncomfortable truths. Lancet. 2024; 403: 2455.

[9] Caserta LC, Frye EA, Butt SL, Laverack M, Nooruzzaman M, Covaleda LM, et al. Spillover of highly pathogenic avian influenza H5N1 virus to dairy cattle. Nature. 2024; 634: 669–676.

[10] Burrough ER, Magstadt DR, Petersen B, Timmermans SJ, Gauger PC, Zhang J, et al. Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus infection in domestic dairy cattle and cats, United States, 2024. Emerging Infect Dis. 2024; 30: 1335–1343.

[11] Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA. 2011; 108: 5354–5359.

[12] Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015; 17: 690–703.

[13] Pradhan D, Biswasroy P, Kar B, Bhuyan SK, Ghosh G, Rath G. Clinical interventions and budding applications of probiotics in the treatment and prevention of viral infections. Arch Med Res. 2022; 53: 122–130.

[14] Taylor FC, Frankl HD, Riemer KD. Late presentation of splenic trauma after routine colonoscopy. Am J Gastroenterol. 1989; 84: 442–443.

[15] Rao S, Hu S, Mchugh L, Lueders K, Henry K, Zhao Q, et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci USA. 2005; 102: 11993–11998.

[16] Sonnenborn U. Escherichia coli strain Nissle 1917–from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol Lett. 2016; 363: fnw212.

[17] Dacquay LC, Tsang D, Chan D, Parkinson J, Philpott DJ, Mcmillen DR. E.coli Nissle increases transcription of flagella assembly and formate hydrogenlyase genes in response to colitis. Gut Microbes. 2021; 13:1994832.

[18] Park J, Kim DH, Kim S, Ma HW, Park IS, Son M, et al. Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model. Intest Res. 2021; 19: 478–481.

[19] Rodríguez-Nogales A, Algieri F, Garrido-Mesa J, Vezza T, Utrilla MP, Chueca N, et al. The administration of Escherichia coli Nissle 1917 ameliorates development of dss-induced colitis in mice. Front Pharmacol. 2018; 9: 468.

[20] Kruis W. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004; 53: 1617–1623.

[21] Frick JS, Fink K, Kahl F, Niemiec MJ, Quitadamo M, Schenk K, et al. Identification of commensal bacterial strains that modulate Yersinia enterocolitica and dextran sodium sulfate-induced inflammatory responses: implications for the development of probiotics. Infect Immun. 2007; 75: 3490–3497.

[22] Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKC? Redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 2007; 9: 804–816.

[23] Alvarez CS, Badia J, Bosch M, Giménez R, Baldomà L. Outer membrane vesicles and soluble factors released by probiotic Escherichia coli Nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. Front Microbiol. 2016; 7: 1981.

[24] Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human β-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through Flagellin. Infect Immun. 2007; 75: 2399–2407.

[25] Huang L, Tang W, He L, Li M, Lin X, Hu A, et al. Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice. Nat Commun. 2024; 15: 6802.

[26] Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009; 460: 1021–1025.

[27] Liu Q, Zhou Y, Yang Z. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016; 13: 3–10.

[28] Cheng HY, Ning MX, Chen DK, Ma WT. Interactions between the gut microbiota and the host innate immune response against pathogens. Front Immunol. 2019; 10: 607.

[29] Wirusanti NI, Baldridge MT, Harris VC. Microbiota regulation of viral infections through interferon signaling. Trends Microbiol. 2022; 30: 778–792.

[30] Ou G, Xu H, Wu J, Wang S, Chen Y, Deng L, et al. The gut-lung axis in influenza A: the role of gut microbiota in immune balance. Front Immunol. 2023; 14:1147724.

[31] Li L, Qiu N, Meng Y, Wang C, Mine Y, Keast R, et al. Preserved egg white alleviates DSS-induced colitis n mice through the reduction of oxidative stress, modulation of inflammatory cytokines, NF-κB, MAPK and gut microbiota composition. Food Sci Hum Wellness. 2023; 12: 312–323.

[32] Wu M, Li P, An Y, Ren J, Yan D, Cui J, et al. Phloretin ameliorates dextran sulfate sodium-induced ulcerative colitis in mice by regulating the gut microbiota. Pharmacol Res. 2019; 150:104489.

[33] Yu Z, Li D, Sun H. Herba Origani alleviated DSS-induced ulcerative colitis in mice through remolding gut microbiota to regulate bile acid and short-chain fatty acid metabolisms. Biomed Pharmacother. 2023; 161:114409.

[34] Stojanov S, Berlec A, Štrukelj B. The influence of probiotics on the Firmicutes/Bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms. 2020; 8: 1715.

[35] Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. Mucosal Immunol. 2019; 12: 843–850.

[36] Effendi SSW, Ng IS. Prospective and challenges of live bacterial therapeutics from a superhero Escherichia coli Nissle 1917. Crit Rev Microbiol. 2023; 49: 611–627.

[37] Long JS, Mistry B, Haslam SM, Barclay WS. Host and viral determinants of influenza A virus species specificity. Nat Rev Microbiol. 2019; 17: 67–81.

[38] Julkunen I. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev. 2001; 12: 171–180.

[39] Rex DaB, Keshava Prasad TS, Kandasamy RK. Revisiting regulated cell death responses in viral infections. Int J Mol Sci. 2022; 23: 7023.

[40] Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012; 76: 16–32.

[41] Guo XJ, Thomas PG. New fronts emerge in the influenza cytokine storm. Semin Immunopathol. 2017; 39: 541–550.

[42] Rosshart SP, Vassallo BG, Angeletti D, Hutchinson DS, Morgan AP, Takeda K, et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell. 2017; 171: 1015–1028.e13.

[43] Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019; 7: 14.

[44] Zhang Q, Hu J, Feng JW, Hu XT, Wang T, Gong WX, et al. Influenza infection elicits an expansion of gut population of endogenous Bifidobacterium animalis which protects mice against infection. Genome Biol. 2020; 21: 99.

[45] Ma L, Ni Y, Wang Z, Tu W, Ni L, Zhuge F, et al. Spermidine improves gut barrier integrity and gut microbiota function in diet-induced obese mice. Gut Microbes. 2020; 12: 1832857.

[46] Lagkouvardos I, Lesker TR, Hitch TCA, Gálvez EJC, Smit N, Neuhaus K, et al. Sequence and cultivation study of Muribaculaceae reveals novel species, host preference, and functional potential of this yet undescribed family. Microbiome. 2019; 7: 28.

[47] Chung Y, Ryu Y, An BC, Yoon YS, Choi O, Kim TY, et al. A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota. Microbiome. 2021; 9: 122.

[48] Takahashi Y, Park J, Hosomi K, Yamada T, Kobayashi A, Yamaguchi Y, et al. Analysis of oral microbiota in Japanese oral cancer patients using 16S rRNA sequencing. J Oral Biosci. 2019; 61: 120–128.

[49] Ganly I, Yang L, Giese RA, Hao Y, Nossa CW, Morris LGT, et al. Periodontal pathogens are a risk factor of oral cavity squamous cell carcinoma, independent of tobacco and alcohol and human papillomavirus. Int J Cancer. 2019; 145: 775–784.

[50] Hu X, Zhao Y, Yang Y, Gong W, Sun X, Yang L, et al. Akkermansia muciniphila improves host defense against influenza virus infection. Front Microbiol. 2020; 11:586476.

[51] Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019; 20: 1279–1290.

[52] Bernasconi R, Jones RSG, Bittiger H, Olpe HR, Heid J, Martin P, et al. Does pipecolic acid interact with the central GABA-ergic system? J Neural Transm. 1986; 67: 175–189.

[53] Zhang N, Wang X, Feng M, Li M, Wang J, Yang H, et al. Early-life exercise induces immunometabolic epigenetic modification enhancing anti-inflammatory immunity in middle-aged male mice. Nat Commun. 2024; 15: 3103.

[54] Yuan X, Chen B, Duan Z, Xia Z, Ding Y, Chen T, et al. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes. 2021; 13:1987779.

[55] Li H, Xiao H, Yuan L, Yan B, Pan Y, Tian P, et al. Protective effect of L-pipecolic acid on constipation in C57BL/6 mice based on gut microbiome and serum metabolomic. BMC Microbiol. 2023; 23: 144.

[56] Vranova V, Lojkova L, Rejsek K, Formanek P. Significance of the natural occurrence of L- versus D-pipecolic acid: a review. Chirality. 2013; 25: 823–831.

[57] Gouesbet G, Jebbar M, Talibart R, Bernard T, Blanco C. Pipecolic acid is an osmoprotectant for Escherichia coli taken up by the general osmoporters ProU and ProP. Microbiology. 1994; 140: 2415–2422.

[58] Mihalik SJ, Moser HW, Watkins PA, Danks DM, Poulos A, Rhead WJ. Peroxisomal L-pipecolic acid oxidation is deficient in liver from Zellweger syndrome patients. Pediatr Res. 1989; 25: 548–552.

[59] Matthews DE. Review of lysine metabolism with a focus on humans. J Nutr. 2020; 150: 2548S–2555S.

[60] Fujita T, Hada T, Higashino K. Origin of D- and L-pipecolic acid in human physiological fluids: a study of the catabolic mechanism to pipecolic acid using the lysine loading test. Clin Chim Acta. 1999; 287: 145–156.

[61] Chen MF, Weng KF, Huang SY, Liu YC, Tseng SN, Ojcius DM, et al. Pretreatment with a heat-killed probiotic modulates monocyte chemoattractant protein-1 and reduces the pathogenicity of influenza and enterovirus 71 infections. Mucosal Immunol. 2017; 10: 215–227.

[62] Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res. 2011; 92: 329–340.

[63] Karakus U, Crameri M, Lanz C, Yángüez E. Propagation and titration of influenza viruses. Methods Mol Biol. 2018; 1836: 59–88.

[64] Yu G, Xu C, Zhang D, Ju F, Ni Y. MetOrigin: discriminating the origins of microbial metabolites for integrative analysis of the gut microbiome and metabolome. IMeta. 2022; 1:e10.

RIGHTS & PERMISSIONS

2025 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.